fda_recall · drug_recall · high
Baxter Healthcare Corporation — Class II recall: Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), Fo…
- Event date
- 2024-02-28 00:00:00Z
- Observed
- 2026-07-16 23:20:09Z
- Source ID
- D-0336-2024
- Payload hash
- 1c3e9976c57ea1d9c2853c4c…
Summary
Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg / 250 mL. Status: Ongoing.
Entities
Frequently asked questions
- Has Baxter Healthcare Corporation had other FDA enforcement actions?
- Yes. Argus HQ has recorded 208 total FDA actions tied to Baxter Healthcare Corporation: 0 warning letters, 208 recalls, 0 approval records, and 0 Form 483 inspection citations.
- What kind of FDA record is this?
- This is an Argus HQ record of a FDA Recall, tagged high severity by Argus HQ. FDA published the underlying record on 2024-02-28; Argus observed and indexed it on 2026-07-16.
- Where can I verify this record directly with FDA?
- The verbatim FDA source record is the source of truth — Argus HQ links directly to it below. Always confirm against fda.gov before acting.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
APA
Argus HQ Research (2024). Baxter Healthcare Corporation — Class II recall: Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), Fo…. Digital Empire LLC. Retrieved from https://argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0336-2024
MLA
"Baxter Healthcare Corporation — Class II recall: Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), Fo…." Argus HQ Research, Digital Empire LLC, 2024, argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0336-2024.
Chicago
Argus HQ Research. "Baxter Healthcare Corporation — Class II recall: Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), Fo…." Digital Empire LLC. Accessed July 17, 2026. https://argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0336-2024.
BibTeX
@misc{argushq_argushq_ai_events_fda_recall_baxter_healthcare_corporation_d_0336_2024_2024,
title = {Baxter Healthcare Corporation — Class II recall: Norepinephrine Bitartrate in 5% Dextrose Injection, 8 mg/ 250 mL (32 mcg/mL), Fo…},
author = {{Argus HQ Research}},
year = {2024},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/events/fda-recall-baxter-healthcare-corporation-d-0336-2024},
note = {Accessed: July 17, 2026}
}Informational only. Not legal, financial, or medical advice.

